Ataru Igarashi

Sep 29, 2024 | redjournal.org | Ataru Igarashi |Outcomes Research |Nagoya City |Imaging Clinic

Introduction Lung cancer has been the leading cause of death among all types of cancers since 1998, with 126,548 people having received diagnoses of lung cancer in 2019 in Japan.1 Non-small cell lung cancer (NSCLC) accounts for 90% of all the whole lung cancer cases in Japan.2 According to recent clinical practice guidelines published by the Japan Lung Cancer Society in 2023, surgery is recommended as the first choice for medically operable patients with stage I NSCLC,3 with stereotactic body...

Jul 18, 2023 | futuremedicine.com | Ataru Igarashi |Kanae Togo |Yasuhiro Kobayashi |Kazumasa Kamei

Future VirologyAhead of PrintResearch ArticleOpen AccessAbstractObjective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants.